ESOPHAGEAL ADENOCARCINOMA

This phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo s…

This phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into th…

This early-stage trial tests NRM-823, a drug designed to help the immune system fight cancer, in 150 people with advanced solid tumors like lung, breast, and ovarian cancer. The study gives NRM-823 alone or with another immunotherapy to see if it is safe and tolerable. The main g…

This study tests an experimental drug called zongertinib, which blocks HER2—a protein that fuels cancer growth. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to standard treatments. Participants receive zongertin…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study tests whether adding metformin or rosiglitazone (drugs used for diabetes) to standard immunotherapy (anti-PD-1) can help shrink tumors or slow cancer growth in people with advanced solid tumors like melanoma, lung cancer, or liver cancer. About 72 participants will be …

This study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.

This study compares two standard approaches for Barrett's esophagus with low-grade dysplasia: regular monitoring with biopsies (surveillance) versus a procedure to remove or burn away precancerous cells (endoscopic eradication therapy). Researchers want to find out which method i…

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study tests a new experimental drug (PF-08634404) given with chemotherapy to people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new co…

This early-stage trial tests a new drug, sigvotatug vedotin, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find the safest dose and check for side effects, both when the drug is used alone and with other cancer treatments. Ab…

This study looks at people with esophageal or stomach cancer that has spread to only a few spots (oligometastases). All participants get 4 months of standard therapy, then are randomly assigned to either 4 more months of drugs before local treatment (surgery or radiation) or imme…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This trial is testing a new, less invasive way to detect Barrett's esophagus, a condition that can lead to esophageal cancer. Participants swallow a capsule attached to a string that expands into a sponge in the stomach, collecting cells as it is pulled back up. The goal is to se…

This study tests whether obeticholic acid can prevent Barrett's esophagus from progressing to esophageal cancer. Barrett's esophagus is a condition where the lining of the food pipe changes due to stomach acid and bile exposure, raising cancer risk. The drug works by reducing bil…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This pilot study is checking if people with eating disorders who have been purging (vomiting or ruminating) for at least 5 years have developed Barrett's esophagus, a condition that can lead to cancer. Researchers will use a simple, non-endoscopic device called EsoGuard to collec…

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the amount of cancer left at the edges of the removed tissue affects how long people live. No new treatments are given; the study only looks at past informati…